Sanofi Licenses Dual JAK/SYK Inhibitor Gusacitinib from Formation Bio in €545 Million Deal
Key Insights
Sanofi has licensed gusacitinib, an oral dual JAK (search)/SYK (search) inhibitor, from Formation Bio (search)'s subsidiary Libertas Bio (search) in a deal worth up to €545 million including upfront payments, milestones, and low to mid-teen royalties.
The pharmaceutical giant will explore gusacitinib's potential in a new indication not previously studied through a phase 1 clinical trial, leveraging its global drug development expertise.
This transaction exemplifies Formation Bio (search)'s AI-native business model of acquiring high-potential clinical-stage assets and partnering at key development inflection points.
Formation Bio (search) announced that its subsidiary Libertas Bio (search) has licensed gusacitinib, an oral dual JAK (search)/SYK (search) inhibitor, to Sanofi in a transaction potentially worth up to €545 million. The deal includes upfront and milestone payments, as well as low to mid-teen royalties based on future sales, positioning Sanofi to explore the compound's therapeutic potential in previously unstudied indications.
Strategic Asset Transfer
Sanofi will advance gusacitinib through a phase 1 study to investigate its potential in a new indication not previously explored. The pharmaceutical giant plans to leverage its global expertise in drug development and commercialization to unlock the compound's therapeutic value in this novel application.
Gusacitinib was originally acquired by Formation Bio (search) in late 2022 from Asana BioSciences (search) as part of a broader portfolio of investigational medicines. This latest transaction represents the compound's transition into its next development stage under Sanofi's stewardship.
Collaborative Partnership Framework
The licensing agreement builds upon several long-standing collaborations between Formation Bio (search) and Sanofi, which have focused on identifying high-potential assets and co-developing AI tools that leverage shared data and technical expertise. This transaction further strengthens both companies' commitment to advancing promising therapies through innovative technology and scientific excellence.
"Formation Bio (search) is redefining drug development through radical efficiency at every step. We acquire high-potential assets, move quickly to unlock value, and partner at key inflection points. We're proud to have Sanofi as a world-class partner working together to accelerate innovation in medicine," commented Benjamine Liu, Co-Founder & CEO of Formation Bio.
Business Model Innovation
This transaction exemplifies Formation Bio (search)'s differentiated approach as an AI-native pharmaceutical company. The company's business model centers on identifying and acquiring high-potential clinical-stage assets, then partnering at strategic development milestones to maximize therapeutic impact and commercial potential.
Formation Bio (search) has built proprietary technology and AI platforms, processes, and capabilities designed to accelerate all aspects of drug development and clinical trials. The company partners, acquires, or in-licenses drugs from pharmaceutical companies and biotechnology firms to develop programs past clinical proof of concept and beyond.